For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Eli Lilly Aims for $100 Billion Revenue Milestone with Strong Growth Projections

Aug 24, 2026
Eli Lilly Aims for $100 Billion Revenue Milestone with Strong Growth Projections

is setting its sights on a significant revenue milestone of $100 billion by fiscal 2026, with management guiding for revenues between $85 billion and $87 billion. This ambitious target is underpinned by the company's strong performance in the incretin market, particularly through its products Mounjaro and Zepbound. Currently trading at $1,255.40, Eli Lilly has a price target of $1,480, indicating a potential upside of nearly 18% over the next year.

In recent weeks, Eli Lilly's stock has seen notable gains, rising 6.38% over the past week and 77.98% over the past year, as it approaches its 52-week high of $1,292.65. The company's second-quarter results for 2026 showcased a revenue of $22.97 billion, marking a year-over-year growth of 47.67%, which exceeded analyst expectations.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

The growth trajectory is largely driven by the incretin franchise, which generated nearly $14.87 billion in a single quarter, with Mounjaro's international sales surging by 172%. Additionally, the anticipated global rollout of orforglipron in 2027 and the upcoming BLA for retatrutide in Q1 2027 are expected to further bolster revenue streams.

CEO David Ricks expressed optimism about the company's future, stating that it has never been brighter in its 150-year history. Analysts maintain a positive outlook, with a consensus of five strong-buy and 17 buy ratings, projecting a bull-case scenario price of $1,704.19, which reflects a total return of approximately 35.75%.

However, risks remain, particularly concerning revenue concentration, as Mounjaro and Zepbound account for over half of Eli Lilly's revenue. The competitive landscape is also evolving, with Novo Nordisk's Wegovy entering the oral GLP-1 market, which could impact Eli Lilly's market share.

Despite these challenges, Eli Lilly's forward P/E ratio of 35 is considered defensible given its growth prospects. The company continues to invest heavily in its pipeline, which includes promising candidates like Verve and Ataibeckley, while also managing the implications of recent IPR&D charges.

Overall, Eli Lilly's strategic positioning and robust product pipeline suggest a strong potential for achieving its ambitious revenue goals, making it a focal point for investors in the tech stock sector.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
NVIDIA vs. Eli Lilly: A Decade-Long Stock Comparison
Tech Stocks Sep 21, 2026

NVIDIA vs. Eli Lilly: A Decade-Long Stock Comparison

NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)